4.8 Article

Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype

Journal

NATURE MEDICINE
Volume 16, Issue 1, Pages 49-U84

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nm.2054

Keywords

-

Funding

  1. Canadian Institutes of Health Research (CIHR) [MOP 89976]
  2. Leukemia and Lymphoma Society of Canada
  3. Canadian Cancer Society
  4. Terry Fox Foundation
  5. Stem Cell Network
  6. Michael Smith Foundation for Health Research (MSFHR)

Ask authors/readers for more resources

5q-syndrome is a subtype of myelodysplastic syndrome characterized by severe anemia and variable neutropenia but normal or high platelet counts with dysplastic megakaryocytes. We examined expression of microRNAs (miRNAs) encoded on chromosome 5q as a possible cause of haploinsufficiency. We show that deletion of chromosome 5q correlates with loss of two miRNAs that are abundant in hematopoietic stem/progenitor cells (HSPCs), miR-145 and miR-146a, and we identify Toll-interleukin-1 receptor domain-containing adaptor protein (TIRAP) and tumor necrosis factor receptor-associated factor-6 (TRAF6) as respective targets of these miRNAs. TIRAP is known to lie upstream of TRAF6 in innate immune signaling. Knockdown of miR-145 and miR-146a together or enforced expression of TRAF6 in mouse HSPCs resulted in thrombocytosis, mild neutropenia and megakaryocytic dysplasia. A subset of mice transplanted with TRAF6-expressing marrow progressed either to marrow failure or acute myeloid leukemia. Thus, inappropriate activation of innate immune signals in HSPCs phenocopies several clinical features of 5q-syndrome.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available